SLR on Clinical Efficacy for Health Technology Assessments
SLR for HTA, meeting clinically relevant PICOs and global market access standards.
Designed for: HTA submissions and reimbursement dossiers in key markets.
Scope: Comprehensive SLR aligned with method requirements for CDA, EU JCA, NICE, and reporting requirements of PRISMA.
Protocol: Developed to meet international standards and PICO-specific objectives.
Screening: Assumes up to 8,000 records screened, using dual screening and conflict resolution.
Extraction: Data extraction on clinically relevant elements from up to 120 eligible reports.
Risk of bias: Assessed using Cochrane RoB v2.0, with quality considerations for subsequent evidence synthesis.
Reporting: Detailed report including PRISMA flow diagram, tabulated summaries by PICO, and findings structured for HTA submissions.
Timeline: 20 weeks
SLR for HTA, meeting clinically relevant PICOs and global market access standards.
Designed for: HTA submissions and reimbursement dossiers in key markets.
Scope: Comprehensive SLR aligned with method requirements for CDA, EU JCA, NICE, and reporting requirements of PRISMA.
Protocol: Developed to meet international standards and PICO-specific objectives.
Screening: Assumes up to 8,000 records screened, using dual screening and conflict resolution.
Extraction: Data extraction on clinically relevant elements from up to 120 eligible reports.
Risk of bias: Assessed using Cochrane RoB v2.0, with quality considerations for subsequent evidence synthesis.
Reporting: Detailed report including PRISMA flow diagram, tabulated summaries by PICO, and findings structured for HTA submissions.
Timeline: 20 weeks
SLR for HTA, meeting clinically relevant PICOs and global market access standards.
Designed for: HTA submissions and reimbursement dossiers in key markets.
Scope: Comprehensive SLR aligned with method requirements for CDA, EU JCA, NICE, and reporting requirements of PRISMA.
Protocol: Developed to meet international standards and PICO-specific objectives.
Screening: Assumes up to 8,000 records screened, using dual screening and conflict resolution.
Extraction: Data extraction on clinically relevant elements from up to 120 eligible reports.
Risk of bias: Assessed using Cochrane RoB v2.0, with quality considerations for subsequent evidence synthesis.
Reporting: Detailed report including PRISMA flow diagram, tabulated summaries by PICO, and findings structured for HTA submissions.
Timeline: 20 weeks